CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab

 
• By Joseph Haas

Troubled leronlimab is placed on partial clinical hold in HIV, full clinical hold in COVID-19. While searching for a new CEO, CytoDyn tries to reassure investors about its business plan going forward.

Cease and desist
A pair of FDA clinical holds create further questions around leronlimab • Source: Alamy

More from Strategy

More from Business